NEW YORK (GenomeWeb) – Interpace Diagnostics reported on Thursday a 42 percent increase in its fourth quarter revenues on growing sales and reimbursement of its thyroid tests.

For the three-month period ended Dec. 31, Interpace's revenues climbed to $4.4 million from $3.1 million in the same period the year before. Contributing to the increase was the continued expansion of payor coverage for the company's ThyGenX and ThyraMir tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.